Korro Bio’s treatment of alpha-1 antitrypsin deficiency gets orphan designation
Korro Bio’s (KRRO) treatment of alpha-1 antitrypsin deficiency received FDA orphan designation, according to a post on the agency’s stie.Light ...
Yahoo Finance10d
Korro Bio, Inc. (KRRO)
CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based ...
Hosted on MSN29d
Korro secures approvals in Australia to commence AATD trial of KRRO-110
Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).
Benzinga.com7d
Korro Bio Stock Price, Quotes and Forecasts
Explore Korro Bio stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KRRO. U.S. stocks reacted positively following the Federal Open Market Committee's ...
Yahoo Finance19d
Korro to Present at the TD Cowen 45th Annual Health Care Conference
Korro Bio, Inc. CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of ...
CNN1mon
Korro Bio, Inc.
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua ...
Benzinga.com5mon
Korro Bio Insider Trading Activity | NASDAQ:KRRO | Benzinga
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...